Corin says this allows the company a greater chance of success in its clinical study for drug candidate QBM-001, as these new biomarkers clearly define the patient population.
Q BioMed discovers two key biomarkers in study of pediatric nonverbal autism
Quick facts: Q BioMed Inc.
Price: 2.25 USD
Market Cap: $46.88 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE